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ABSTRACT
TRAIL has been extensively explored as a cancer drug based on its tumor-selective 
activity profile but it is incapable per se of discriminating between death receptors 
expressed by normal host cells and transformed cancer cells. Furthermore, it is well 
documented that surface tethering substantially increases its biologic activity. We have 
previously reported on Meso-TR3, a constitutive TRAIL trimer targeted to the biomarker 
MUC16 (CA125), in which the entire ectodomain of human mesothelin was genetically 
fused to the TR3 platform, facilitating attachment to the cancer cells via the MUC16 
receptor. Here, we designed a truncation variant, in which the minimal 64 amino acid 
MUC16 binding domain of mesothelin was incorporated into TR3. It turned out that the 
dual-domain biologic Meso64-TR3 retained its high MUC16 affinity and bound to the 
cancer cells quickly, independent of the TR3/death receptor interaction. Furthermore, 
it was substantially more potent than Meso-TR3 and TR3 in vitro and in a preclinical 
xenograft model of MUC16-dependent ovarian cancer. Phenotypically, Meso64-TR3 is 
more closely related to non-targeted TR3, evident by indistinguishable activity profiles 
on MUC16-deficient cancers and similar thermal stability characteristics. Overall, 
Meso64-TR3 represents a fully human, MUC16-targetd TRAIL-based biologic, ideally 
suited for exploring preclinical and clinical evaluation studies in MUC16-dependent 
malignancies.
INTRODUCTION
Tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) was discovered in the mid 1990’s as a 
new member of the large tumor necrosis factor (TNF) 
superfamily and caught immediate attention as a promising 
cancer therapeutic [1–4]. Viewed as the most favorable 
property of TRAIL as a drug candidate was the fact that it 
selectively induced apoptosis in transformed tumor cells but 
not in normal cells in vivo, without causing toxicity following 
systemic applications [5–7], one of the key discoveries 
among members of the TNF superfamily [8, 9]. TRAIL exerts 
its biological functions via binding to cell surface-expressed 
death receptors DR4 and DR5 [10–14], which triggers cell 
death through activation of the extrinsic apoptosis pathway 
[15], mediated via death receptor clustering and the formation 
of the death-inducing signaling complex (DISC) with the 
involvement of the initiator caspase-8 and the executioner 
caspase-3, ultimately leading to programmed cell death [16–
19]. Moreover, it turned out that TRAIL acted independently 
of p53, which suggested that chemotherapy-resistant tumors 
caused by inactivating mutations of this tumor suppressor 
were still sensitive to TRAIL-based therapies [11, 20, 21]. 
Based on these features, a number of clinical trials have been 
initiated, while numerous attempts to develop more potent 
TRAIL variants were concurrently explored, including 
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stabilization with trimerization domains (leucine zipper 
[LZ]), formation of higher-order TRAIL complexes and 
genetic fusions with the constant regions (Fc) of human 
immunoglobulins [22–24].
In this regard, we have pioneered an entirely new 
concept to generate constitutively trimerized TRAIL 
biologics via genetic engineering. This novel drug design 
was created by covalently linking three TRAIL ectodomains 
into a single fusion protein, designated TR3, characterized 
by enhanced stability and apoptosis induction capacity and 
the ability for downstream modification options in a modular 
and stoichiometrically fully-controlled fashion [25]. The 
latter aspect has far reaching consequences with respect to 
developing truly tumor-targeted TR3 biologics, selective 
for a given cell surface biomarker. This targeting concept is 
particularly attractive not only for the site-specific delivery 
and the accumulation of the therapeutics at the tumor cell 
membrane, it converts soluble TR3 drugs into membrane-
bound analogs, a process which substantially increases death 
receptor signaling and thereby the overall bioactivity of the 
therapeutic [26]. More specifically, by taking advantage of 
the high affinity interaction between mesothelin and MUC16 
[27], we recently designed a mesothelin/TR3 fusion protein, 
designated Meso-TR3, in order to tether our therapeutic to the 
MUC16 biomarker located on the tumor cell membrane [28].
Even though Meso-TR3 demonstrated several 
favorable properties, such as improved bioactivity on 
MUC16-expressing tumors in vitro and in vivo, we 
suspected that it’s relatively large molecular weight could 
prove prohibitive when it comes to drug penetration into 
solid tumors, as these are often characterized by extensive 
stromal components, especially relevant in pancreatic 
cancer [29, 30]. Based on this consideration and the notion 
that the amino-terminal 64 amino acids of mesothelin have 
been described to be sufficient to facilitate binding to native 
MUC16 [Ref. [31]], we designed a Meso-TR3 truncation 
variant, designated Meso64-TR3. Here, we describe the 
properties of this re-designed, MUC16-targeted TR3 
trimer in a head-to-head comparison with its full length 
first-generation predecessor and demonstrate its unaltered 
MUC16 binding capacity combined with improved stability 
and superior biologic activity. We identified the high affinity 
of the mesothelin/MUC16 interaction as the dominant 
parameter for the rapid attachment of targeted TR3 fusion 
proteins to MUC16-positive cancer cells with the TR3/DR 
interaction playing a secondary role. We thus believe that 
Meso64-TR3 will be widely applicable for the treatment 
of MUC16-positive malignancies, including ovarian, breast 
and pancreatic cancers [32–34].
RESULTS
Meso64-TR3 retains strong binding capacity to 
MUC16-expressing cancer cells
Our previously described MUC16-targeted cancer 
drug Meso-TR3 contained the peptide sequence of the 
entire mature ectodomain of human mesothelin fused to 
the N-terminus of TR3 [28]. However, Meso-TR3 is a 
rather bulky molecule and contains several mesothelin-
derived glycosylation sites, which heavily contribute to its 
large molecular weight. Along these lines, and in an effort 
to reduce the molecular weight of MUC16-targeted Meso-
TR3, it has been shown that the 64 N-terminal amino acids 
of mesothelin are sufficient to facilitate strong interaction 
with MUC16 [35]. These considerations prompted us to 
design a truncation variant by inserting the corresponding 
64 amino acid mesothelin-encoding cDNA into the 
5’-terminus of the TR3 expression platform (Figure 
1A). Both MUC16-targeted recombinant fusion proteins 
contain an N-terminal FLAG epitope tag for immunologic 
detection purposes (not shown). The proteins were 
produced in HEK293T cells and their molecular weight 
was confirmed by Western blot analysis. With ≈65 kDa, 
Meso64-TR3 was only ≈5 kDa larger (+8%) than parental 
TR3 (≈61 kDa) and ≈35 kDa smaller (-35%) than Meso-
TR3 (≈100 kDa) (Figure 1B).
Due to the drastically reduced targeting domain, an 
initial concern was the ability of Meso64-TR3 to interact 
efficiently with native MUC16. We therefore performed 
confocal microscopy following drug exposure employing 
the MUC16-positive ovarian cancer cell line OVCAR3. 
Since Meso64-TR3 represents a dual-domain therapeutic 
(a MUC16 interacting-, and a death receptor effector 
domain), two possible binding mechanisms had to be 
distinguished: the TR3/death receptor interaction (DR4, 
DR5, DcR1 and DcR2) and the mesothelin/MUC16 
interaction. In order to prevent drug binding via the 
TR3/DR interaction, Meso64-TR3 was complexed with 
soluble death receptor 5 (DR5-Fc), prior to exposure to 
the cancer cells [28]. Confocal microscopy confirmed a 
signal overlap between the MUC16 marker and surface-
tethered Meso64-TR3 (Figure 1C). These initial results 
were highly encouraging and suggested that the minimal 
MUC16 binding domain of human mesothelin (amino 
acids 1 - 64) was indeed sufficient to tether Meso64-TR3 
to the OVCAR3 cell membrane. Similar binding results 
were obtained in other cancer cell types, such as HeLa 
(cervical cancer) and HPAC (pancreatic cancer), both 
characterized by more heterogenous MUC16 expression 
profiles (see below).
Meso64-TR3 shares functional similarity with 
TR3 on MUC16-negative cells but is a much 
stronger apoptosis-inducer than Meso-TR3 on 
MUC16-expressing cancer cells
Our TRAIL-based biologics are characterized by 
a multi-domain architecture, a biomarker recognition 
domain (mesothelin) and the activation domain of the 
extrinsic death pathway (TR3). In an attempt to shed light 
on the isolated functionality of the TR3 effector domain, 
we treated TRAIL-sensitive, MUC16-deficient Jurkat cells 
with our biologics. All of our drugs induced target cell 
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death in a dose-dependent fashion. Of note, at equimolar 
concentrations, Meso64-TR3’s activity profile exactly 
matched that of non-targeted TR3, whereas Meso-TR3’s 
potency was substantially reduced, consistent with our 
previous report (Figure 2A). Similar activity profiles were 
obtained for all three drugs on other cell types known to be 
largely devoid of MUC16-expression, again highlighting 
the similarity between Meso64-TR3 and non-targeted 
TR3 relative to Meso-TR3 (Figure 2B, BxPC3 pancreatic 
cancer).
Most importantly, however, when all three drugs 
were tested on MUC16-positive ovarian cancer cells, 
Meso64-TR3 was capable of eradicating nearly all target 
cells (92%), followed by Meso-TR3 (59%) and TR3 (14%) 
(Figure 2C). Moreover, when TR3 and Meso64-TR3 were 
tested in a preclinical model of MUC16-positive ovarian 
cancer, the targeted drug variant outperformed its non-
targeted analog with regard to a delay in tumor growth 
(Figure 2D), which corresponded with a significant life 
extension of the animals, with median survivals of 23.5 
days (control), 26.5 days (TR3) and 32.5 days (Meso64-
TR3), respectively (Figure 2E). These results were very 
encouraging and suggest that the N-terminal 64 amino 
acids of mesothelin are not only sufficient to facilitate 
efficient binding to native MUC16, it converts Meso64-
TR3 into a much more powerful cancer drug that retains 
its enhanced in vitro activity profile in a preclinical mouse 
model of ovarian cancer.
Meso64-TR3-mediated cancer cell death is 
consistent with apoptosis
Whenever modifications are introduced into an 
established drug candidate, such as TR3, it is crucial to 
perform a series of validation experiments to ensure 
that key characteristics are retained in the drug variant. 
Figure 1: Design and binding profile of targeted Meso64-TR3 on MUC16-expressing cancer cells. A. Schematic 
representation of the proteins designed for this study. All proteins are based on the TR3 drug platform. The first generation, MUC16-targeted 
TRAIL trimer Meso-TR3 contains the entire mesothelin ectodomain as delivery vehicle (red and green; CHO, O-linked glycosylation 
sites). Meso64-TR3 represents a MUC16-targeted TR3 trimer in which only the 64 amino-terminal amino acids of mesothelin were used 
as delivery moiety (green). Both targeted biologics contain N-terminal FLAG tags for immunologic detection purposes. B. Western blot 
analysis (reducing conditions) documents the molecular weights of TR3 (≈60 kDa, lane 2), Meso-TR3 (≈100 kDa, lane 4) and Meso64-
TR3 (≈65 kDa, lane 3) using anti-TRAIL pAb. Supernatant from mock-transfected HEK293T cells served as a negative control (lane 1). 
C. MUC16-expressing OVCAR3 cells were grown on 8-chamber EZ slides and incubated the following day with Meso64-TR3 complexed 
with DR5-Fc. After washing, the cells were stained with anti-MUC16 pAb (red) and anti-FLAG mAb (green), respectively. The cells were 
counterstained with TOPRO3 (blue, nuclei) and analyzed by confocal microscopy. The individual channels were overlaid to document co-
localization of the tumor marker and the targeted cancer drug (Overlay). Original magnification: 40x.
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These considerations also apply to the MUC16-targeted 
truncation variant Meso64-TR3. In order to verify 
that the enhanced activity profile of Meso64-TR3 was 
indeed related to its membrane tethering to MUC16, 
soluble mesothelin was used to block this interaction. 
In the presence of increasing concentrations of soluble 
mesothelin, we noticed a dose-dependent reduction in 
its ability to induce cell death from nearly 80% to below 
53% (Figure 3A). It was further anticipated that, once 
attached to the cancer cell membrane, apoptosis was 
mediated by engagement of the TR3-effector domain with 
membrane-expressed death receptors, especially DR4 
and/or DR5. We thus performed blocking experiments 
employing soluble death receptor 5 (DR5-Fc). When 
OVCAR3 cells were treated with Meso64-TR3 in the 
presence of increasing concentrations of DR5-Fc, a dose-
dependent reduction of cell death was accomplished from 
92% (no inhibitor) to 11% at the highest concentration of 
the inhibitor (Figure 3B). Similar results were seen with 
MUC16-deficient Jurkat cells (data not shown). These data 
support the notion that Meso64-TR3 does indeed require 
engagement with activating death receptors at the plasma 
cell membrane to induce cancer cell death.
The previous experiments provided circumstantial 
evidence for the activation of the extrinsic death pathway 
being responsible for the improved properties of Meso64-
TR3 on MUC16-positive cancer cells. To further solidify 
these presumptions, we performed additional biochemical 
analyses regarding the key players involved in the 
activation and execution of apoptosis, caspases-8,-9, and 
-3. First, we treated OVCAR3 cells with TR3 and Meso64-
TR3 for 24 h, prepared cell lysates and assessed the 
activation status of the most proximal signaling molecule 
relative to the death receptors, caspase-8, by Western 
blot analysis. Consistent with the strong activity profile 
of Meso64-TR3 on these cells, we did notice a robust 
induction of activated cleavage fragments of caspase-8, 
along with a reduction in the signal intensity of its 
precursor. This activation pattern was absent for both the 
TR3 and non-treated control cells (Figure 3C). To verify 
these initial results, we determined the activation profiles 
of caspases-8, -3 and -9 using a different assay system 
Figure 2: Meso64-TR3 unleashes its potency on MUC16-expressing tumor cells in vitro and in vivo. A. Cell killing profiles 
of TR3, Meso-TR3 and Meso64-TR3 at equimolar concentration ranges were established on the MUC16-deficient T cell leukemia cell 
line Jurkat. NS, not significant; *, P < 0.03. B. Similar result was repeated on another nearly MUC16-deficient pancreatic cancer cell line 
BxPC3. NS, not significant; **, P < 0.007. C. The same killing assay as in (A) using identical drug concentrations but the MUC16-positive 
ovarian cancer cell line OVCAR3 instead. *, P < 0.02; ***, P < 0.0002. D. Nude mice with established subcutaneous flank tumors were 
treated daily for 13 days with 655 pmoles TR3, Meso64-TR3 and PBS only (control). Tumor sizes were measured using electronic calipers. 
****, P < 0.0001. E. Kaplan-Mayer survival curve of the drug-treated mice shown in (D). Mice were considered dead after the tumors 
exceeded 1000 mm3. ****, P < 0.0001.
Oncotarget5www.impactjournals.com/oncotarget
(Caspase-Glo assay, see M&M for details). This more 
quantitative analysis tool also enabled us to determine 
the kinetics of caspase activation. It turned out that all 
three caspases were activated with the same kinetics, 
with an activation peak around four hours post-treatment 
(Figure 3D). The importance of caspase activation as a 
mediator of Meso64-TR3-dependent cancer cell death was 
finally confirmed using the pan-caspase inhibitor Z-VAD-
FMK. This irreversible inhibitor of intracellular caspase 
activation completely protected OVCAR3 cells from 
apoptosis (Figure 3E). Taken together, the strong death-
inducing properties of Meso64-TR3 were found to depend 
Figure 3: Phenotypic characterization of MUC16-targeted Meso64-TR3. A. OVCAR3 cells were challenged with a constant 
amount of Meso64-TR3 (80% specific cell death) and increasing concentrations of soluble mesothelin to study the impact of the mesothelin/
MUC16 interaction of Meso64-TR3. B. OVCAR3 cells were challenged with a constant amount of Meso64-TR3 (90% specific cell death) 
and increasing concentrations of DR5-Fc to verify involvement of the extrinsic death pathway as a mechanism of Meso64-TR3-induced 
cell death. C. OVCAR3 cells were seeded in 6-well plates and treated for 4 hours with TR3, Meso64-TR3 and medium as control. The cell 
pellets were submitted to Western blot analysis to examine the expression and activation status of caspase-8. D. OVCAR3 cells were seeded 
in 96-well plates and treated with Meso64-TR3 for 2, 4, 6, 8 h and the activity of caspase-3, caspase-8 and caspase-9 were detected using 
Caspase-Glo reagent. E. OVCAR3 cells were treated with a constant amount of Meso64-TR3 (90% specific cell death) in the presence of 
Z-VAD-FMK, a pan-caspase inhibitor to block the extrinsic death pathway. Cells treated with DMSO were used as a control. Error bars, 
mean ± SD. Results are representatives of at least 2 independent experiments done in triplicates. NS, not significant; ****P < 0.0001.
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on membrane tethering to the cancer biomarker MUC16 
and was confirmed to be consistent with key attributes 
of death receptor-mediated, caspase-dependent forms of 
programmed cell death - apoptosis.
Meso64-TR3 is a temperature-stabilized 
monomer
In order to complete the characterization phase 
of Meso64-TR3, we exposed our novel cancer drug to 
physiologic and elevated temperature conditions and 
assessed the impact of these parameters on the respective 
structural components of the dual-domain therapeutics 
(the targeting and the effector domain). Initially, we 
exposed TR3, Meso-TR3 and Meso64-TR3 to elevated, 
non-physiologic temperature conditions (60 min at 56 
ºC) and studied the effects on the TR3 effector domain 
of the fusion proteins using MUC16-negative Jurkat cells. 
Under these conditions, Meso-TR3 lost more than 70% of 
its initial killing capacity, while Meso64-TR3 and TR3 lost 
less than 25% of their initial activities (Figure 4A, Jurkat). 
The same trend was noticed when the drugs were assessed 
on MUC16-expressing OVCAR3 cells. While Meso-TR3 
lost nearly 64% of its baseline killing capacity, Meso64-
TR3 lost only 19% (Figure 4B, OVCAR3). Both of these 
results further underscore the high phenotypic similarities 
Figure 4: Meso64-TR3 is a temperature-stabilized monomer. A. TR3, Meso-TR3 and Meso64-TR3 were treated at 56°C for 60 
minutes and the effect on the killing capacity was evaluated on MUC16-deficient Jurkat cells (temperature influence on the TR3 effector 
domain). NS, not significant; *P < 0.02. B. TR3, Meso-TR3 and Meso64-TR3 were treated at 56°C for 60 minutes and the effect on 
the killing capacity was evaluated on MUC16-positive OVCAR3 cells (temperature influence on the MUC16 targeting domain effector 
domain). ***P < 0.0005. C. Meso-TR3 and Meso64-TR3 were incubated at 37°C for up to seven days and the effect on the killing capacity 
was evaluated on OVCAR3 cells. **P < 0.002. D. BxPC3 cells (MUC16-low) were treated with low-dose Meso64-TR3 (24% specific cell 
death) in the presence of increasing concentrations of anti-FLAG mAb to facilitate drug dimerization, which is associated with an increase 
in DR5 signaling and apoptosis induction. Cells treated with anti-FLAG mAb alone served as a control. **P < 0.004.
Oncotarget7www.impactjournals.com/oncotarget
between TR3 and Meso64-TR3, which are in contrast 
to the more temperature-sensitive and less active fusion 
protein Meso-TR3. Under less stringent temperature 
conditions (physiologic 37 ºC) but extended storage time 
(1 - 7 days), the same trend was noted. After an entire 
week of incubation at 37 ºC, Meso64-TR3 retained nearly 
all of its killing capacity on OVCAR3 cells (90%), while 
Meso-TR3 lost its activity quickly to only 40% of its 
initial potency (Figure 4C).
In our previous study, we reported on the 
monomeric nature of Meso-TR3, which was based on 
experimental evidence that following crosslinking with 
a mesothelin-specific monoclonal antibody, a drastic 
increase in bioactivity was achieved on MUC16-negative 
Jurkat cells [28]. Since truncated Meso64-TR3 did likely 
no longer contain the binding epitope for this mAb, we 
used an antibody directed against the FLAG epitope tag of 
our fusion proteins. When BxPC3 pancreatic cancer cells 
were treated with a sublethal dose of Meso64-TR3 (~25% 
cell death) in the presence of the anti-FLAG monoclonal 
antibody M2, we could demonstrate a dose-dependent 
augmentation of cell death to nearly 80% at the highest 
concentration of cross-linking antibody (Figure 4D). 
These results strongly suggest that Meso64-TR3 is indeed 
a monomer in solution that can be functionally enhanced 
by forming homodimers via antibody crosslinking.
Targeted Meso64-TR3 selectively eliminates 
MUC16-positive cancer cells
It was predicted that the enhanced killing capacity 
of Meso64-TR3 was mediated by a selective delivery 
mechanism to MUC16-positive cells, followed by 
induction of apoptosis through TR3/DR interaction [28]. 
If this was true, we anticipated that MUC16-positive 
cancer cells should be preferentially eliminated from a 
heterogeneous mix of positive and negative cells. The 
human cervical cancer cell line HeLa is an example of 
a native mix of MUC16-positive and negative cells. 
Confocal microscopy was employed to identify the various 
expression levels on different cells within the mix. After 
treating the cells with Meso64-TR3/DR5-Fc complexes 
(necessary to prevent binding directly via TR3, compare 
Figure 1C), we identified MUC16-negative cells that also 
lacked the signal for our cancer drug (Figure 5A, DR5-
Fc[+], arrows).
In order to study a potential hierarchy of binding 
events and/or affinities of our dual-domain therapeutic 
(mesothelin/MUC16 vs. TR3/DR), we treated HeLa cells 
only briefly (10 min) with Meso64-TR3 in the absence 
of TR3-blockade (no DR5-Fc complex formation). Even 
under these conditions, we obtained similar staining 
profiles as in the presence of TR3-blockade, with areas 
lacking signals for both MUC16 and Meso64-TR3 (Figure 
5A, DR5-Fc[-], dashed line). These data gave us first clues 
regarding the hierarchy of binding events and suggest that 
the high affinity of the mesothelin/MUC16 interaction 
likely dominates the TR3/DR interaction of the fusion 
protein and leads to a quick absorption of Meso64-TR3 
by MUC16-expressing cells (see below for a more detailed 
analysis using an extrinsic pathway sensitizer to reveal this 
phenomenon).
We next used more quantitative means (flow 
cytometry) to document the selective killing capacity 
of Meso64-TR3 on MUC16-positive cancer cells. For 
this experiment, we treated HeLa cells, a native mix 
of MUC16-positive and -negative cells, with TR3 and 
Meso64-TR3. Several days later, the cells were analyzed 
for their MUC16 expression profiles. While TR3 alone was 
unable to alter the MUC16 ratio, similar to the untreated 
control cells, treatment with Meso64-TR3 decreased the 
number of MUC16-positive cells by nearly 70% (Figure 
5B, 5C). These findings support our binding data in that 
the MUC16-positive cells are selectively targeted and 
eliminated by Meso64-TR3, a feature not shared with non-
targeted TR3.
Meso64-TR3 retains MUC16-selective killing 
properties in cancers refractory to TRAIL 
monotherapy
It is well known that not all cancers are equally 
responsive to TRAIL treatment. In fact, some cancers are 
quite resistant with regard to apoptosis induced via the 
extrinsic death pathway. Fortunately, an ever increasing 
number of sensitizing agents of the TRAIL death receptor 
pathway are available and have been studied extensively, 
including targeted SMAC mimetics [36–39]. In order to 
assess the potential benefit of a MUC16-targeted TR3 
variant over its non-targeted counterpart on MUC16-
positive cells that are refractory to TRAIL treatment, we 
took advantage of our recently designed, cancer-targeted 
small molecule SMAC mimetic SW IV-134 [40, 41]. It 
was predicted to be ideally suited to augment the extrinsic 
death pathway due to its dual activity profile involving 
cIAP degradation and XIAP blockade. In our current 
study, we explored the pathway sensitizer SW IV-134 in 
an effort to document the differential killing characteristics 
between MUC16-targeted and non-targeted forms of TR3.
To determine the optimal drug doses for the 
assessment of additive/synergistic treatment effects, 
OVCAR3 cells (TRAIL-sensitive, 100% MUC16+) were 
treated with increasing concentrations of TR3, Meso64-
TR3 and SW IV-134. At picomolar concentrations, TR3 
and Meso64-TR3 displayed their characteristic activity 
profiles with Meso64-TR3 being substantially more 
potent than TR3 (Figures 6A and 6B). SW IV-134 induced 
cell death in a dose-depending fashion consistent with 
previously published data and required a low micromolar 
concentration range [40]. When both drugs were combined 
additively, the cells responded to the drugs much stronger. 
At the lowest concentration of each agent (43.5 pM 
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TRAIL drugs and 2 µM SW IV-134), TR3’s killing 
capacity increased only to ~20%, while Meso64-TR3 
killed more than 90% of the cells (Figures 6A and 6B). In 
order to achieve nearly complete tumor cell elimination 
following combination therapy with TR3, a 3-fold higher 
molar concentration of TR3 and a 4-fold higher SW IV-
134 concentration were required (Figure 6A and 6B; 130.6 
pM TR3 + 8 µM SW IV-134 versus 43.5 pM Meso64-
TR3 + 2 µM SW IV-134, black arrows). Combination 
therapy substantially reduced the amounts of drugs 
needed to achieve complete tumor cell death with 5-fold 
less Meso64-TR3 and 8-fold-less SW IV-134 (Figure 6B, 
compare black and open arrow). The strong sensitizing 
effect of SW IV-134 during Meso64-TR3 co-treatment 
was suggestive of a synergistic cell death mechanism. 
We thus repeated this experiment by lowering both drug 
doses during combination treatment (Supplementary 
Figure S1A). Mathematical modeling using CompuSyn 
software [42] confirmed a synergistic rather than an 
additive drug effect with a combination index (CI) < 1 
(range: 0.16 - 0.63) (Supplementary Figure S1B).
We next repeated the above experiment with the 
TRAIL-refractory cell lines HPAC (pancreatic cancer) 
and HeLa (cervical cancer), both comprised of a 50% - 
80% mixture of MUC16-expressing cells. Even though 
both cell lines express varying levels of MUC16, 
treatment with targeted and non-targeted TR3 variants 
was rather inefficient and did not cause significant cell 
death within the indicated concentration range (Figures 
6C and 6E). However, following pathway sensitization 
with SW IV-134 (4 µM constant dose), MUC16-targeted 
Meso64-TR3 outperformed its non-targeted counterpart 
in both instances (Figures 6D and 6F). Of note, and 
only following combination treatment, Meso64-TR3 
Figure 5: Meso64-TR3 preferentially binds to MUC16-expressing tumor cells via the high affinity mesothelin/MUC16 
interaction. A. HeLa cells were grown on 8-chamber EZ slides and incubated the following day with Meso64-TR3 complexed with and 
without DR5-Fc. After washing, the cells were stained with anti-MUC16 pAb (red) and anti-FLAG mAb (green), respectively. The cells 
were counterstained with TOPRO3 (blue, nuclei) and analyzed by confocal microscopy. The individual channels were overlaid to document 
co-localization of tumor marker and the targeted cancer drug (Overlay). Original magnification: 40x. B. HeLa cells were treated with TR3 
(blue) and Meso64-TR3 (green) for 24 hours. Two days post-treatment, the cells were stained with anti-MUC16 antibody (mAb X75) and 
assessed for changes in the MUC16 ratio using flow cytometry. Representative histogram overlays are shown from experiments done at 
least twice in triplicates. C. Graphic representation of the data shown in (B). Error bars, mean ± SD. NS, not significant; ****P < 0.0001.
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selectively eliminated the MUC16-positive cells from 
a mixed population of HPAC pancreatic cancer cells 
(Supplementary Figure S2A and S2B). These data are 
in agreement with a selective accumulation of targeted 
Meso64-TR3 on biomarker-expressing cancer cells, a 
process that is independent of the TR3/DR interaction 
(Supplementary Figure S2C). Along these lines, 
combination treatment of pancreatic cancer cells with 
absent (or nearly undetectable) MUC16 expression did 
not result in a differential killing profile between the two 
TRAIL drugs (Supplementary Figure S3).
The mesothelin/MUC16 interaction dominates 
the TR3/death receptor interaction of the dual-
domain biologic Meso64-TR3
Functional cell viability data suggested that Meso-
TR3 and Meso64-TR3 appeared to have much higher 
affinity to MUC16-expressing cancer cells than non-
targeted TR3. However, the corresponding assays were 
usually performed following a 24 h drug exposure. In 
order to unequivocally proof this hypothesis, we designed 
an experiment in which OVCAR3 cells (100% MUC16-
Figure 6: Pathway sensitization reveals the full potential of MUC16-targeted Meso64-TR3 in both TRAIL sensitive 
and refractory cancer cells. Cell viability determinations were performed on TRAIL sensitive OVCAR3 cells (A. and B. 100% 
MUC16) and the TRAIL refractory cells HPAC (C. and D. 50% MUC16) and HeLa (E. and F. 60%- 80% MUC16). In order to 
illustrate the benefit of MUC16 targeting, OVCAR3 cells were treated with TR3 (A), Meso64-TR3 (B) and SW IV-134 (A, B) alone and in 
combination with each other at increasing concentrations of both cancer drugs. Please note that the drug concentrations required to achieve 
close to 100% target cell death using combination therapy (solid arrows) are much reduced for Meso64-TR3 compared to the drugs used in 
isolation (open arrow). The killing capacities of TR3 and Meso64-TR3 were also studied on cells that were refractory to TRAIL treatment 
in the absence (C; HPAC, NS, not significant and E; HeLa, NS, not significant) and in the presence of pathway sensitization using constant 
doses of SW IV-134 (D; HPAC, **P < 0.004 and F; HeLa, **P < 0.003).
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positive) were exposed for short time periods (5 - 60 min) 
to equimolar concentrations of the TR3 drugs (targeted 
or non-targeted), washed extensively to remove the non-
bound biologics, followed by a 24 h exposure to the 
pathway sensitizer SW IV-134. This two-step design 
allowed us to separate initial drug binding events from 
pathway amplification, primarily as an experimental tool, 
necessary due to the limited activity profile of TR3 on 
OVCAR3 cells.
And indeed, we noticed a time-dependent increase 
in overall cell killing capacity for all TR3 drugs in 
combination with SW IV-134 (baseline activity: 31%). 
The most dramatic effect was seen with Meso64-TR3, 
approaching 95% cell death induction after only a five 
minute binding interval (Figure 7). Prolongation of the 
binding time did not increase cell death induction and 
suggests that Meso64-TR3 saturated the cancer cell 
membrane quickly within the first five minutes of drug 
exposure. Meso-TR3 required a 60 minute binding time to 
achieve maximum target cell killing (94%), followed by 
TR3 (can only bind via DR interaction) with a 70% killing 
maximum at the one hour drug exposure mark. Overall, 
the time-response killing curves obtained following 
pathway sensitization with SW IV-134 closely mimic 
the dose-response activity profiles for the respective 
TR3 drugs when used alone (compare Figure 2C) and 
highlight the benefits of tethering TR3-based therapeutics 
to the cancer cells via the high-affinity interaction between 
mesothelin and MUC16.
DISCUSSION
Cancer therapy usually offers only a narrow 
window of opportunity when it comes to finding the most 
appropriate drug doses while limiting toxic side effects 
for the patients. In this regard, TRAIL has garnered 
tremendous interest as a cancer drug as it has demonstrated 
tumor-selective activity profiles without being toxic to the 
host. Along these lines, it is important to point out that 
the native cytokine, as well as our recently designed drug 
platform TR3, does not have the capacity per se to actively 
discriminate between transformed cancer cells and healthy 
Figure 7: Meso64-TR3’s enhanced activity profile is dominated by its much enhanced binding affinity and rapid 
surface tethering to MUC16-positive cancer cells. OVCAR3 cells were exposed for the indicated time points to TR3, Meso-TR3 
and Meso64-TR3 (218 pM each). Then, the cells were washed three times with PBS in order to remove the unbound biologics, followed 
by treatment of all cells with a constant dose SW IV-134 for additional 24 hours (8 μM), after which cell viability was determined. Please 
note that in order to achieve close to complete target cell death, Meso64-TR3 required only a five minute binding interval, not matched by 
TR3 and not even Meso-TR3. P < 0.003.
Oncotarget11www.impactjournals.com/oncotarget
host tissues. These non-transformed host tissues, including 
certain immune effector cells, have been shown to express 
various TRAIL receptors and act primarily as a “sink” 
for TRAIL-based therapeutics [43–45], but are protected 
from the cytokine by intracellular cFLIP expression [43]. 
Furthermore, other non-immune host cells, under certain 
inflammatory conditions, can even become susceptible 
to TRAIL therapy, a potential cause of undesirable side 
effects [46–48].
Over the years, various recombinant TRAIL 
variants have been engineered to enhance the stability 
and pharmacologic potency of the cytokine but, much 
to our surprise, truly cancer-targeted variants have not 
yet been tested in clinical trials. In order to endow the 
TRAIL cytokine with tumor selectivity and to minimize 
potential off-target toxicities, targeting moieties need to 
be incorporated into the therapeutics. Such downstream 
modifications would not only ensure accumulation of 
the therapeutics at the tumor site, it tethers the drugs 
via biomarker association to the tumor cell surface. 
This membrane conversion has been shown to result 
in far more robust death receptor signaling events than 
the non-targeted parental variants can ever accomplish 
[28, 49, 50].
In this study, we built on our previously established 
drug platform TR3 [25] and generated a truncation variant 
of Meso-TR3 [28], designated Meso64-TR3, representing 
a functionally improved, next generation TRAIL-based 
cancer therapeutic targeted to the biomarker MUC16.
Meso-TR3 is a rather bulky molecule with a 
molecular weight of more than 100 kDa, primarily due to 
its extended secondary structure (amino acid sequence), 
relative to the more compact structural organization of 
Meso64-TR3. By eliminating more than 75% of the 
C-terminal region of the mesothelin targeting moiety, 
three putative glycosylation sites were removed, which 
contributed significantly to the molecular weight loss 
relative to Meso-TR3. Also, it has been known for a while 
[27] and recently confirmed [35] that the amino-terminal 
64 amino acids of mesothelin were sufficient to facilitate 
efficient binding to MUC16. Our current study was thus 
primarily designed as a proof-of-concept to assess if such 
a short peptide sequence would still facilitate binding 
to native MUC16, especially in the context of a fusion 
protein with a TR3 effector domain being nearly 6.5-fold 
the size of the 64 amino acid mesothelin binding moiety. 
We were therefore encouraged to see that Meso64-TR3’s 
binding affinity to the MUC16 biomarker was not only 
retained but resulted in a much more potent cancer drug 
compared to its full length predecessor on MUC16-
positive tumor cells. On the other hand, it turned out that 
Meso64-TR3 and TR3 were functionally indistinguishable 
on MUC16-negative cancer cells (Jurkat and other, nearly 
MUC16-negative cancer cells, such as BxPC3), while 
Meso-TR3 showed a markedly reduced activity profile 
on these cells, in accordance with its previously proposed 
prodrug feature [28]. We can only speculate about the 
reason(s) for Meso64-TR3 being much more potent 
than Meso-TR3 on MUC16-expressing cancer cells but 
we believe that the high sensitivity of the full length 
mesothelin targeting moiety to elevated (56 ˚C) and even 
to physiologically more relevant temperature conditions 
(37 ˚C) might be a key discriminating factor for Meso-
TR3’s reduced functional properties.
While in the process of characterizing this novel 
cancer drug candidate on a mechanistic level, we 
confirmed that key extrinsic pathway components were 
engaged following Meso64-TR3 treatment. In addition, 
biophysical analyses demonstrated much enhanced 
thermal stability of Meso64-TR3 over Meso-TR3 on 
MUC16-positive and -negative cancer cells, acting as a 
monomer in solution with a preference to eliminate the 
cells it binds. Along these lines, the substantially enhanced 
activity profile of Meso64-TR3 compared to TR3 on 
OVCAR3 cells is quite remarkable, given that these cells 
have been reported to be nearly resistant to TRAIL due to 
MUC16-dependent upregulation of cFLIP and a reduction 
in DR5 expression [51]. Thus, despite these unfavorable 
circumstances, we could demonstrate that membrane 
tethering to MUC16 with Meso64-TR3 (and Meso-TR3 
to a lesser extend) could indeed overcome the therapeutic 
plateau observed with non-targeted TRAIL variants.
Furthermore, we shed new light on potential 
hierarchies with respect to epitope preferences, primarily 
responsible for initial drug binding events at the cancer 
cell membrane. Since MUC16-targeted TR3 represents a 
dual-domain therapeutic, at least two binding scenarios 
can be discriminated – 1. the mesothelin/biomarker 
(MUC16) interaction and 2. the TR3/death receptor 
interaction. In our previous study, we addressed this 
ambiguity by preincubating the targeted reagent (Meso-
TR3) with soluble death receptor (DR5-Fc), to ensure that 
the binding process to MUC16 was exclusively mediated 
by the mesothelin targeting moiety of the fusion protein 
[28]. In our current study, we assessed this aspect in 
greater detail and included experiments in which complex 
formation with DR5-Fc was omitted. Confocal imaging 
data suggested that the strong affinity of mesothelin 
to MUC16, including our latest data on the 64 amino-
acid truncation variant Meso64-TR3, dominated during 
the attachment process over the native death receptor 
interaction, since the staining patterns in the presence 
and absence of death receptor blockade turned out to be 
indistinguishable.
In an attempt to further confirm our imaging results 
and to demonstrate the advantage of using targeted 
versus non-targeted TR3 therapeutics for cancer therapy, 
we designed experiments in which the extrinsic death 
pathway was sensitized with an activator of the intrinsic 
pathway using the small molecule drug conjugate SW IV-
134 [40, 41]. We could indeed show that extrinsic pathway 
sensitization with SW IV-134 had a much stronger effect 
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for targeted TR3 therapy than non-targeted TR3 by 
shifting the therapeutic index further to lower overall 
drug concentrations in combination with Meso64-TR3 
on various cancer cell lines exhibiting varying MUC16 
expression levels. When this pathway sensitizer was 
incorporated in a time-dependent, “functional binding” 
assay, we could demonstrate that Meso64-TR3 required 
the shortest exposure time to achieve the highest target 
cell deaths, followed by Meso-TR3 and the non-targeted 
TR3 parent. These results highlight the positive impact 
of a high biomarker affinity for the development of 
targeted TR3-based drugs in order to ensure efficient drug 
accumulation on the cancer targets, thereby preventing 
systemic toxicities during future preclinical and clinical 
investigations. Along these lines, we are currently in the 
process of confirming the enhanced uptake properties of 
MUC16-targeted Meso64-TR3 by the tumors in vivo, in 
relation to its non-targeted TR3 counterpart.
And finally, another important aspect regarding the 
mesothelin/MUC16 interaction is its potential contribution 
to homotypic (tumor cell-tumor cell) and heterotypic (tumor 
cell-mesothelial cell) cell interactions, especially important 
for the peritoneal spread in ovarian cancer patients [52]. The 
latter type of interaction is believed to promote adherence 
of tumor cells to the peritoneum, resulting in metastatic 
spread of the primary lesion into the abdomen [27, 53, 54]. 
These considerations suggest that by binding to MUC16, 
Meso64-TR3 may also saturate and reduce or even eliminate 
the available binding sites on the biomarker for adhesive 
interactions with mesothelin-expressing normal endothelium, 
thereby limiting the dissemination of tumor cells in addition 
to augmenting TRAIL-mediated target cell death [55].
Taken together, we predict that the strong affinity 
of Meso64-TR3 to native MUC16, combined with its 
favorable thermal stability and monomeric character are 
key ingredients for a successful clinical application. We 
further anticipate that the high affinity of Meso64-TR3 
to the MUC16 biomarker facilitates rapid absorption and 
accumulation of the systemic drug by the tumors and 
results in a fast clearance from the bloodstream. Once 
tethered to the cancer cells in vitro and in vivo, pathway 
sensitization is further expected to enhance treatment 
efficacy while systemic off-target toxicities are predicted to 
be kept at a minimum. Thus, systematic pharmacokinetic/ 
pharmacodynamic (PK/PD) studies of our targeted cancer 
therapeutics (biologics and small molecule conjugates) are 
clearly warranted to further demonstrate a treatment benefit 
of targeted combination therapy in preclinical animal 
studies in preparation for future clinical trials.
MATERIALS AND METHODS
Cells and reagents
All cell lines (OVCAR3, HeLa, HPAC, BxPC3, 
AsPC-1, HEK293T) used in the experiments were 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA). Recombinant human TRAIL was 
purchased from Enzo Life Science (formerly BIOMOL, 
International, Farmingdale, NY). The sigma-2/SMAC 
drug conjugate SW IV-134 was synthesized as previously 
reported [40]. Cell viability was detected using luciferase-
based readout (CellTiter-Glo, Promega, Madison, WI). 
Caspase activation was determined employing Caspase-
Glo Assay System (Promega, Madison, WI). The pan-
caspase inhibitor Z-VAD-FMK was purchased from Enzo 
Life Sciences (Ann Arbor, MI).
Plasmid construction and protein production
The basic TR3 expression plasmid [25], soluble 
mesothelin and Meso-TR3 were generated as previously 
described [28]. Meso64-TR3 was generated via insertion 
of a 261 bp BsiWI/Asp718 (compatible with BsiWI) PCR 
fragment into the unique BsiWI restriction site of the TR3 
expression platform, verified by DNA sequencing. All 
recombinant TR3 forms, soluble mesothelin, and DR5-
Fc were produced in HEK293T cells under serum-free 
conditions as described [25, 28]. To obtain concentrated 
protein stocks, the supernatants were applied to centrifugal 
filter devices with a 10 kDa molecular cut-off (Centricon 
Plus-20, Millipore, Billerica, MA). DR5-Fc was purified 
using Protein A columns as per the manufacturer’s 
instructions (Pierce, Rockford, IL).
Analysis of cell death
Cells were seeded into 96 well plates at the 
respective optimal densities (1x104 for OVCAR3 and 
HeLa cells, 5x104 for Jurkat cells, 2x104 for BxPC3 and 
AsPC-1 cells, and 1.5x104for HPAC cells). Treatment 
was initiated the following day and cell viability was 
determined 18 hours after treatment using CellTiter-
Glo Luminescent Viability Assay according to the 
manufacturer’s instructions (Promega Madison, WI). 
The treatment conditions involved the various TRAIL 
variants alone (TR3, Meso-TR3 and Meso64-TR3) and 
combinations with SW IV-134 (drug binding/combination 
experiments); DR5-Fc, mesothelin and Z-VAD-FMK 
(blocking experiments) and anti-FLAG mAb (dimer 
formation experiment). Data were recorded using a Multi-
Detection Microplate Reader (Synergy HT, BioTek, 
Winooski, VT).
Caspase activation assays
Caspase-3, -8, and -9 activities were detected in 
OVCAR3 cells treated with Meso64-TR3 employing 
a Caspase-Glo Assay System according to the 
manufacturer’s instructions (Promega, Madison, WI). 
OVCAR3 cells were seeded at a density of 1x104 in 96 
well plates and then treated for 2, 4, 6 and 8 hours with 
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Meso64-TR3 the following day. 100 µL of caspase reagent 
was added into each well, mixed for 30 seconds using a 
plate shaker, and incubated for 90 additional minutes 
at room temperature. This assay system is based on the 
caspase-specific substrate activation by the respective 
caspases. Luminescence was measured using a multi-
mode microplate reader (Bio-Tek).
Western blot analysis
OVCAR3 cells were seeded in 10 cm plates and 
treated for 4 hours with vehicle, TR3 or Meso64-TR3 
the following day. After washing twice with PBS, the 
cells were lysed in RIPA lysis buffer supplemented with 
complete protease inhibitor cocktail (Roche, Mannheim, 
Germany). The lysates were centrifuged at 14,000 rpm 
for 15 minutes and the supernatants were collected. The 
samples (30 µL for each treatment condition) were run 
on a 4-12% Bis-Tris polyacrylamide gradient gel and 
transferred to a PVDF membrane using an iBlot 2 Gel 
Transfer Device (Life Technologies, Carlsbad, CA). 
The PVDF membrane was incubated at 4 ˚C for 24 
hours with a mouse anti-caspase-8 mAb (Cell Signalling 
Technology, Danvers, MA), followed by a 1 hours 
incubation at room temperature with HRP-conjugated 
goat anti-mouse IgG secondary antibody (Santa Cruz 
Biotech, Dallas, TX). Immunoreactive bands were 
visualized using ClarityTM Western ECL Substrate (Bio-
Rad Laboratories, Hercules, CA).
Flow cytometry
To assess the selective killing capacity of Meso64-
TR3 on MUC16-positive tumor cells, HeLa and HPAC 
cells (1.5x105/well and 3x105/well, respectively) were 
seeded into 6-well plates for 24 hours before treatment 
with TR3, Meso64-TR3 or medium (control) in the 
absence or presence of 4 µM SW IV-134 (to amplify the 
TRAIL-induced extrinsic death pathway). After incubation 
at 37 ˚C for 24 hours, the supernatants were replaced 
by fresh medium and the cells were allowed to grow to 
sub-confluence. Cells were washed and harvested non-
enzymatically (EDTA). The cells were then incubated 
with anti-MUC16 mAb X75 (Abcam, Cambridge, MA), 
followed by staining with FITC-conjugated secondary 
antibody (anti-mouse IgG, Sigma-Aldrich, St. Louis, 
MO) and submitted to flow cytometry (FACSCalibur, BD 
Biosciences, San Jose, CA).
Confocal microscopy
OVCAR3, HeLa and HPAC cells were cultured for 
24 hours on millicell EZ slides (Millipore, Billerica, MA) 
and treated the following day. In order to prevent binding 
of Meso64-TR3 via TR3/death receptor interaction, 
Meso64-TR3 was complexed with DR5-Fc (between 5 
and 30 minutes). After washing with PBS and fixation 
with 4% paraformaldehyde, the cells were blocked with 
serum-free Protein Block (Dako, Carpinteria, CA). 
Primary antibodies for FLAG (mouse mAb M2) and 
MUC16 (rabbit pAb, Sigma-Aldrich) were allowed to bind 
for 2 h, washed and detected with the respective secondary 
Abs Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, 
Carlsbad, CA) and Alexa Fluor 555 goat anti-rabbit IgG 
(Invitrogen). Confocal images were taken on a Zeiss LSM 
510 META Confocal Laser Scanning Microscope (Zeiss, 
Jena, Germany).
Time-dependent cell death analysis
To compare the binding capacity of non-targeted 
and MUC16 targeted TRAIL constructs, a binding assay 
was performed by allowing different binding time for 
these three drugs. OVCAR3 cells were seeded in 96-well 
plates (1x104/well) and cultured for 18 hours. Equimolar 
concentrations of TR3, Meso-TR3 and Meso64-TR3 (218 
pM) were added to the wells for 5, 10, 30 and 60 minutes 
before the supernatants were removed and the cells were 
washed three times with PBS to remove traces of unbound 
drugs from the wells. Due to the limited activity of TR3 
on OVCAR3 cells, the pathway sensitizer SW IV-134 (8 
µM) was subsequently added to all wells. Cell death was 
analyzed using CellTiter-Glo Luminescent Viability Assay 
as described above.
Animals
Six to eight week old female Severe Combined 
Immunodeficiency mice (SCID; Harlan, IN) were used as 
hosts for tumor xenografts. Human OVCAR3 tumor pieces 
(2 x 2 mm2) were implanted into the flanks and allowed to 
engraft until reaching a volume of 100 mm3 prior to grouping 
and drug treatment (655 pmoles/mouse/day for 13 days). 
Procedures involving mice were approved by the Washington 
University Animal Studies Committee and conducted in 
accordance with the guidelines for the care and use of 
laboratory research animals established by the NIH.
Statistical analyses
Treatment efficiency of in vitro killing assays and in 
vivo tumor growth rates are presented as means ± SEM. 
Statistical significance for all analyses is defined as P < 
0.05 and was calculated employing analysis of variance 
(one-way ANOVA, Tukey’s Multiple Comparison Test) 
and the Student’s t-test (unpaired) as indicated using 
GraphPad Prism (V 4.02) software.
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